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Human Herpesvirus 8 as a Potential Sexually Transmitted Agent in Honduras
C. Sosa, W. Klaskala, B. Chandran, R. Soto, School of Biological Sciences, University of Nebraska-Lincoln, Lincoln,
Nebraska; Department of Psychiatry, University of Miami School ofL. Sieczkowski, M. H. Wu, M. Baum, and C. Wood
Medicine, and Fogarty International Training Center, Department of
Psychiatry, University of Miami School of Medicine, Miami, Florida;
Department of Microbiology, Molecular Genetics and Immunology,
University of Kansas Medical Center, Kansas City, Kansas
The seroprevalence of human herpesvirus 8 (HHV-8) was studied in 326 human immunodeficiency
virus (HIV)–positive and –negative persons from Honduras; women constituted 77% (n  251) of
the subjects. Sera were tested for lytic HHV-8 antibodies by an IFA, and positive samples were
confirmed by a radioimmunoprecipitation assay. Of the 326 persons tested, 58 (17.8%) had HHV-
8 antibodies. Among the HIV-infected women, 22.7% were seropositive; 11.3% of the HIV-negative
women were seropositive. HHV-8 seroprevalence was almost four times higher in HIV-positive
female commercial sex workers (36%) than in HIV-negative female non–commercial sex workers
(9.9%; odds ratio  3.8, 95% confidence interval  1.1–13; P  0.01), suggesting that commercial
sex work is a risk factor for HHV-8 infection. In the men studied, the overall HHV-8 seroprevalence
was 22.6%, with a seropositivity rate of 28% for HIV-positive men compared with 12% for HIV-
negative men.
Human herpesvirus 8 (HHV-8) has been detected in Kaposi’s showed HHV-8 antibodies in 21% of a small group of HIV-
positive women, in 95% of HIV-infected homosexual mensarcoma (KS) tumors of all clinical forms [1], in lymphomas
[2], in Castleman’s disease [3], and in skin cancers [4]. Several without KS, and in 25% of healthy adults [13].
The aim of our work was to determine the HHV-8 seropreva-B lymphoma cell lines that harbor HHV-8 have been estab-
lished and used for serologic assays [5, 6]. IFA showed that lence and associated risk factors in a population of women and
men in Honduras; in Latin America, the incidence of KS ismost KS patients have specific antibodies to HHV-8–related
antigens [7]. In another study, which used a Western blot assay, low. Determination of the HHV-8 infection in men and women
of this area should provide important information about thean HHV-8 seroprevalence of 80% was reported for KS patients
but for only 18% of human immunodeficiency virus (HIV)– distribution of and risk factors for HHV-8 infection.
positive homosexual men without KS. No positive samples
were identified among healthy blood donors or HIV-positive
men with hemophilia [8]. Similar results were found using a Materials and Methods
recombinant-based Western blot assay: 84% in KS patients,
Patients. Men and women (n  326) attending public clinics1.19% in HIV-positive hemophilic patients, and 3.17% in HIV-
in five cities in Honduras (Tegucigalpa, San Pedro Sula, Comaya-positive intravenous drug users [9].
gua, La Ceiba, and Puerto Tela) were enrolled in the study, whichHIV-positive homosexual men develop KS at a rate 20,000-
is part of an ongoing study on HIV infection by the University offold higher than that in the general population [10]. In contrast,
Miami. The clinics belong to the Honduran Ministry of Health
the incidence of KS in HIV-positive women is only 1%–3%
and provide services free of charge to the general population.
[10, 11]. Recently, a study by Kedes et al. [12] found HHV-8 Participants represented a cross-sectional sampling of the popula-
antibodies in only 4% of HIV-positive versus 1.2% in HIV- tion and were recruited from the five previously mentioned major
negative American women [12]. In contrast, another study public care centers. We deliberately recruited known HIV-positive
individuals when they came for health care so they would comprise
50% of the study population. Individuals were enrolled consecu-
tively into the study during their routine medical checkups at the
Received 10 October 1997; revised 24 February 1998. clinics. All eligible participants were included in the study; how-
All participants signed informed consent forms, including for HIV testing, ever, subjects who attended the clinics more than once were not
and the study received prior approval from the Honduran Ministry of Health. reenrolled in the study.
Financial support: PHS grant 30356 (to C.W. and B.C.); Nebraska Health
Participants with AIDS, intravenous drug users, and hemophili-Foundation grant (to C.W.). C. Sosa is a scholar in the AIDS International
acs were excluded by chart review because the aim of the studyTraining and Research Program at the University of Miami School of Medicine,
sponsored by the Fogarty International Center, NIH (D-43-T-W-0017-09). was to assess factors contributing to sexual transmission of HHV-
Reprints or correspondence: Dr. Charles Wood, School of Biological 8. Intravenous drug usage and blood transfusion would add a non-
Sciences, University of Nebraska-Lincoln, Lincoln, NE 68588-0666
controlled additional risk to the study, such as acquiring HHV-8(cwood1@unl.edu).
by needle sharing or by contaminated blood. Patients with AIDS
The Journal of Infectious Diseases 1998;178:547–51
were excluded because the purpose was to evaluate persons withq 1998 by the Infectious Diseases Society of America. All rights reserved.
0022–1899/98/7802–0035$02.00 intact immune systems in an asymptomatic population.
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A questionnaire was administered to collect sociodemographic Table 1. HHV-8 and human immunodeficiency virus (HIV) sero-
prevalences in selected groups.characteristics and HIV and HHV-8 risk factor information. It
provided information on the age of first sexual intercourse, type,
HHV-8–positive†condom use, and history of sexually transmitted diseases. The
lifetime number of sex partners was not available; however, the
Cutoff point
number of partners in the prior 12 months was self-reported by
HIV serologic
study participants. status* 1:10 1:40
Blood samples were collected for HHV-8 serology and other
tests. Blood samples from all self-reported HIV-positive individu- Women (total  251) (/) 110 (43.8) 25 (22.7) 7 (6.4)
als were tested by ELISA and Western blot at the University of (0) 141 (56.2) 16 (11.3) 5 (3.5)
Non–sex workers (/) 85 (33.9) 16 (18.8) 3 (3.5)Miami School of Medicine. Patients who tested positive for HIV
(0) 71 (28.3) 7 (9.9) 2 (2.8)received counseling at the clinics. HHV-8 testing was not available
Commercial sex workers (/) 25 (10.0) 9 (36.0) 4 (16.0)at the clinics at that time, so information about HHV-8 serologic
(0) 70 (27.9) 9 (12.9) 3 (4.3)status was not given to the patients.
Men (total  75) (/) 50 (66.7) 14 (28.0) 4 (8.0)HHV-8 IFA. IFA was performed to detect HHV-8 antibodies
(0) 25 (33.3) 3 (12.0) 0
according to described procedures [13]. An HHV-8–positive cell
Homosexual (/) 20 (26.7) 7 (35.0) 2 (10.0)
line (BCBL-1; from M. McGrath and D. Ganem via the AIDS (0) 2 (2.7) 0 0
Repository Program [6], NIH), an HHV-8–negative cell line Heterosexual (/) 30 (40.0) 7 (23.3) 2 (6.7)
(BJAB), and an Epstein-Barr virus (EBV) producer cell line (0) 23 (30.7) 3 (13.0) 0
(P3HR-1) were used. Cells were induced with tetradecanoyl phor- Total study population  326 (/) 157 (48.2) 39 (24.8) 11 (7.0)
(0) 169 (51.8) 19 (11.2) 5 (3.0)bal acetate (TPA) and spotted onto slides. Samples were examined
using an epifluorescent microscope, and technicians were not
NOTE. Data are no. (%).aware of the IFA or radioimmunoprecipitation (RIP) results. All
* Percentages were calculated based on total no. of women or men.
samples were coded, and an inverse antibody titer⁄10 was consid- † Percentages were calculated based on HIV serologic status of subgroup.
ered positive.
A reference patient serum (HIV-positive, KS-positive) showed
distinctive IFA lytic patterns of bright, punctuated nuclear and were single. They had 6 years of formal education, and the
cytoplasmic staining in induced BCBL-1 cells. Control normal majority were of low socioeconomic status. Of all individuals,
serum showed no staining. Lytic antigen expression was further 56% lived on the Atlantic coast area, and 44% lived in the
confirmed with an HHV-8–specific anti–ORF 59 monoclonal anti-
country’s interior. First sexual contact was reported at a median
body (11D1). Due to the discrepancies in previous seroprevalence
age of 15 years. More than 52.4% of the participants acknowl-studies, 1:10 and 1:40 cutoff dilutions were both used, and the
edged the use of noninjected drugs, mainly cocaine and alcohol.positive samples were titrated (1:10–1:1280). To eliminate the
Almost all knew about condoms, but only 37% acknowledgedpossibility of EBV cross-reaction, the 1:10 dilution–positive sam-
consistent usage. A history of sexually transmitted diseasesples were preadsorbed using lysates from an EBV producer cell
line (P3HR1). The diluted sera were incubated with cell lysates was reported by 34.4% of the participants.
from 1 1 107 TPA-stimulated P3HR1 cells, and absorbed versus HHV-8 seroprevalence. The frequency of HHV-8–posi-
unabsorbed samples were compared. HHV-8–specific fluorescent tive samples at the 1:10 and 1:40 dilutions was determined
patterns were maintained after absorption, indicating that reactivi- (table 1). Of the 326 persons tested, 58 (17.8%) were positive:
ties at the 1:10 dilution were not due to cross-reaction with EBV. 41 (16.3%) were women, and 17 (22.6%) were men (table 2).
HHV-8 RIP and SDS-PAGE analysis. Ten million uninduced Among the HIV-infected women, an overall HHV-8 seroposi-
or TPA-induced (4–5 days after induction) BCBL-1 cells were
tivity of 22.7% (25/110) at the 1:10 dilution and 6.4% (7/
labeled for 20 h with 25 mCi/mL [35S]methionine (Tran35S label,
110) at the 1:40 dilution was found (table 1). In contrast, thespecific activity, 1177 Ci/mmol; ICN, Irvine, CA). Immunoprecipi-
seropositivity of HHV-8 among HIV-negative women wastation was done as described elsewhere [14]. RIP was performed
11.3% (16/141) at the 1:10 and 3.5% (5/141) at the 1:40 cutoff.with all 1:10 IFA–positive samples to confirm these results.
In the univariate analysis, there were differences between theStatistical analysis. The univariate analysis was used (Epi
Info, version 6.0; CDC, Atlanta) to assess the relative importance proportion of HIV-positive and HIV-negative women who
of various risk factors for HHV-8 infection. Medians and percent- were infected with HHV-8. The HHV-8 seroprevalence was
ages were calculated to compare variables across sexual groups almost four times higher among HIV-positive female sex work-
and their serologic status. Associations with HHV-8, as well as ers (36%) than among HIV-negative non–commercial sex
with HIV and dual HIV plus HHV-8 seropositivity, were measured workers (9.9%; OR  3.8, 95% CI  1.1–13; P  .01), sug-
with odds ratios (ORs) and 95% confidence intervals (CIs). gesting that prostitution and HIV are risks associated with
HHV-8 infection. Information about the numbers of lifetime
sex partners from these two groups of women were not avail-Results
able; however, the correlation between the number of sex part-
ners in the prior 12 months and HHV-8 serologic status wasDemographics and risk factors. Of the 326 participants
recruited, 77% were women (median age, 27 years), and 91% not significant. Our interpretation could still be affected due to
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Table 2. Study groups and selected HHV-8 risk factors.
Total HIV-positive HHV-8–positive* HIV/HHV-8–positive
Women 251 110 (43.8) 41 (16.3) 25 (9.9)
Men 75 50 (66.6) 17 (22.6) 14 (18.6)
Total 326 160 (49.0) 58 (17.8) 39 (12.0)
Risk factors
Homosexual male contact 22 20 (90.9) 7 (31.8) 7 (31.8)
Female sex worker 85 25 (29.4) 18 (21.2) 9 (10.6)
Drug use history 171 89 (52.0) 37 (21.6) 23 (13.4)
Never use condoms 143 80 (55.9) 25 (17.5) 17 (11.9)
History of STDs 112 76 (67.8) 25 (22.3) 18 (16.1)
Abnormal Pap smear 76 43 (56.6) 14 (18.4) 13 (17.1)
NOTE. STDs, sexually transmitted diseases; HIV, human immunodeficiency virus.
* Based on 1:10 dilutions of serum samples.
the limited data on the types of sex partners and the duration reacting viral proteins of the expected sizes: 225, 145, 74, 70,
55, and 23 kDa.of commercial sex work of these women. In men, the overall
HHV-8 seroprevalence was 22.6% (17/75) (table 2). The rate
of HHV-8 infection in HIV-positive men was more than twice
as high as in HIV-uninfected men at the 1:10 dilution (28% Discussion
vs. 12%) (table 1), but these results were not statistically sig-
nificant due to the small sample size. To our knowledge, this is the first comprehensive study to
determine the prevalence of HHV-8 infection in a Latin Ameri-There were also differences in the univariate analysis of the
risks associated with different behaviors (table 2): Being a can country. Our data extend previous serologic reports [7]
linking high HHV-8 seroprevalence with HIV coinfection. Evi-homosexual male (OR  10.0, 95% CI  1.3–92.9, P  .009),
engaging in sexual intercourse at early age (comparison of dence of strong association between HHV-8 and HIV infections
is supported in this study by the fact that HIV-positive womenmeans, 14.6 years, 16.4 years; P  .01), history of sexually
transmitted diseases (OR  3.5, 95% CI  1.6–8.0; P  .01), have almost twice the risk of HHV-8 infection than a similar
group of HIV-negative women. We chose this group becauseand abnormal Pap smear (OR  5.2, 95% CI  1.7–15.9; P
 .006) were significantly associated with dual HIV/HHV-8 the HIV-positive women were very likely to be infected hetero-
sexually and were available for follow-up studies to correlateseropositivity. All variables associated with HIV/HHV-8 sero-
positivity or with an OR  0.75 or 1.5 were then entered the incidence of HHV-8 infection with KS development.
A noticeable lack of consistency in the reported literatureinto a logistic regression model. First sexual activity at ⁄16
years old (adjusted OR  0.4; 95% CI  0.2–0.8; P  .011) of HHV-8 seroprevalence could be related to poor sampling
methods, different levels of test sensitivity (1:10 dilutions vs.and being male (adjusted OR  3.0, 95% CI  1.3–7.0; P 
.012) were independently associated with dual HIV/HHV-8 1:40 as a final cutoff point), and possible variations in assay
formats, including the detection of lytic or latent antibodies.infection. Among the small group of HIV-infected men studied,
sexual orientation was not statistically associated with HHV- Nevertheless, the unique epidemiology of KS seems to support
the hypothesis that the cause of KS is multifactorial and that8 serologic status (OR  1.7, 95% CI  0.5–6.1; P  .4).
RIP. To confirm that weak positive sera (1:10 titer) were one of the cofactors (necessary or enhancing factors) is HHV-
8, which predisposes HIV-positive persons to KS.indeed positive, RIP was performed. Positive sera recognized
at least 20 polypeptides in induced BCBL-1 cells, which are We chose to consider all sera showing reactivities at a 1:10
dilution or above as seropositive in this study because thisprobably proteins associated with lytic HHV-8 antigens (figure
1, lanes 1, 5, 7, 9, 11 [uninduced] and lanes 2, 6, 8, 10, 12 dilution includes more infected patients and, consequently,
shows a more realistic distribution of HHV-8–infected persons.[TPA-induced]). IFA-negative sera did not show a specific
reaction in RIP (figure 1, lanes 3, 4). All sera recognized 155-, Because all these samples were first absorbed with EBV cell
lysate to remove cross-reactivity, we are confident that they116-, 105-, 90-, 55-, 50-, 38-, 29-, and 23-kDa polypeptides
from induced cells. Studies indicate that the 116-, 110-, 90-, reacted solely with HHV-8 antigens. Furthermore, all samples
were tested blindly by IFA at different sites (Nebraska and70-, 55-, and 50-kDa proteins are HHV-8 glycoproteins [14].
Only a weak reaction was seen in the uninduced BCBL-1 cells, Kansas), and all weakly reactive samples were confirmed by
RIP. Finally, our study included a negative control group, pro-and only a limited number of polypeptides (225-, 145-, 74-,
70-, 55-, and 23-kDa) were immunoprecipitated. Positive RIP viding additional confidence that any bias found in the HIV-
positive group would also be found in the control group.criteria were established on the basis of the appearance of
/ 9d4c$$au49 07-01-98 22:03:35 jinfa UC: J Infect
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Figure 1. Radioimmunoprecipitation of selected samples: Lanes 1, 3, 5, 7, 9, and 11 are uninduced BCBL-1 cells. Lanes 2, 4, 6, 8, 10, and
12 are tetradecanoyl phorbal acetate–induced BCBL-1 cells. All cells were labeled with [35S]methionine for 20 h. Lanes 1 and 2 are sera that
were human immunodeficiency virus–positive (HIV) and HHV-8 positive by IFA at titer of 1:640. Lanes 3 and 4 are HIV-positive and HHV-
8–negative (IFA  1:10). Lanes 5–12 are sera positive for HHV-8 by IFA.
Lennette et al. [10] analyzed a small number of HIV-positive negative group. These results could be biased because a sig-
nificant proportion of the HIV-positive women were commer-women and reported an HHV-8 seroprevalence (21%) similar
to that in our study. However, in the HIV-negative group, they cial sex workers; however, having multiple sex partners does
seem to be a major risk factor for HHV-8 infection, suggestingdetected a higher rate (28%). Our study with HIV-positive
women showed higher rates than those reported by Kedes et that HHV-8 can be transmitted heterosexually.
al. [13]. This may be explained by the cutoff (1:40) used in
that study.
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A Randomized, Controlled, Molecular Study of Condylomata Acuminata
Clearance during Treatment with Imiquimod
Stephen K. Tyring, Istvan Arany, Margaret A. Stanley, Departments of Microbiology/Immunology and Dermatology,
University of Texas Medical Branch at Galveston; Department ofMark A. Tomai, Richard L. Miller, Michael H. Smith,
Pathology, University of Cambridge, Cambridge, United Kingdom;Daniel J. McDermott, and Herbert B. Slade
Departments of Pharmacology and Clinical Research, 3M
Pharmaceuticals, St. Paul, Minnesota
Imiquimod, an immune response modifier, has been demonstrated to be safe and effective in the
treatment of external genital and perianal warts caused by human papillomavirus (HPV). To identify
the molecular mechanism(s) by which condylomata acuminata clear during topical treatment with
imiquimod, wart skin biopsies were taken from patients before treatment, at treatment week 6, and
at the end of treatment. Tissues were analyzed for HPV DNA and for mRNA of several cytokines
and HPV gene products. Wart clearance was associated with evidence of tissue production of
interferon-a, -b, and -g and tumor necrosis factor-a. Regression of warts was strongly associated
with a decrease in HPV DNA and in mRNA expression for both early and late viral proteins. Thus,
topical imiquimod treatment of anogenital warts led to significant increases in local production of
multiple interferon mRNAs and a significant reduction in virus load as measured by decreases in
HPV DNA and mRNA for early HPV proteins.
Human papillomavirus (HPV) is the most common sexually cal excision, electrocautery, or laser, as well as cytodestruction
transmitted viral disease. About 1%–2% of the sexually active with podophyllin, podophyllotoxin, or trichloroacetic acid, sug-
population in the United States has genital or perianal warts gesting no clear preference for therapy. The traditional goals of
(condylomata acuminata), caused mainly by HPV types 6 and sexually transmitted disease therapy—eradication of infection,
11 [1]. Current therapies include ablation by cryotherapy, surgi- elimination of symptoms, prevention of long-term sequelae,
and interruption of transmission—have not been attained for
genital warts [2]. The lack of a sustained adaptive immune
response seems to underlie disease, as evidenced by frequency
Received 7 November 1997; revised 19 February 1998. of HPV disease in immunosuppressed patients [3].
Presented in part: 16th International Papillomavirus Conference, Siena, Italy,
Spontaneous regression of anogenital warts occurs in 10%–5–12 September 1997 (abstract T-32).
Informed consent was obtained from each patient in the study following 30% of patients receiving placebo and is associated with cell-
explanation of the procedures to be performed during the study. mediated immunity (CMI) [3, 4]. This suggests that immune
Financial support: 3M Pharmaceuticals.
enhancement may be an alternative to the purely destructiveReprints or correspondence: Dr. Stephen K. Tyring, Dept. of Microbiology
and Immunology, The University of Texas Medical Branch at Galveston, 301 therapies described above. Until recently, injectable interferon
University Blvd., Galveston, TX 77555-1019 (Tyring@flash.net). (IFN), primarily IFN-a, has been the only available therapy
The Journal of Infectious Diseases 1998;178:551–5 able to induce immune-mediated clearance of anogenital
q 1998 by the Infectious Diseases Society of America. All rights reserved.
0022–1899/98/7802–0036$02.00 warts. Patients with warts that respond to IFN therapy have
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